 NEW HAVEN, Conn., Jan. 04, 2023 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco, Calif. 